FDA Approves AbbVie's RINVOQ Therapy For Active Non-Radiographic Axial Spondyloarthritis
October 21 2022 - 5:30PM
Dow Jones News
By Kathryn Hardison
The Food and Drug Administration has approved AbbVie Inc.'s
RINVOQ(R) drug for the treatment of adults with active
non-radiographic axial spondyloarthritis.
The company said Friday that the oral therapy was approved for
people with objective signs of inflammation who have had an
inadequate response or intolerance to tumor necrosis factor blocker
therapy.
This follows the FDA's approval of RINVOQ in April for adults
with active ankylosing spondylitis, the company said.
RINVOQ is also used to treat adults with moderate to severe
rheumatoid arthritis, active psoriatic arthritis and moderate to
severe ulcerative colitis. The drug is also used to treat adults
and children 12 years of age and older with moderate to severe
eczema.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
October 21, 2022 17:15 ET (21:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024